Catalent Capabilities Update June 2026: Cell Line Development

This session explores how transient expression can fundamentally change the pace of biologics development — enabling teams to generate high-quality material and actionable data faster, with less risk. We'll cover how Catalent uses this approach to support candidate selection, process development, and early-stage decisions that keep programs moving.

But transient expression is just the starting point. The presentation will walk through Catalent's full cell line development platform — from stable pool generation through process and analytical development to GMP manufacturing — and show how these capabilities connect into a single, coherent workflow.

That integration matters. When discovery, development, and manufacturing operate as one continuous path rather than a series of handoffs, programs move faster, transfer risks drop, and teams spend less time managing complexity. Attendees will come away with a clear picture of how Catalent's gene-to-IND model works in practice, and what it means to have a partner who can carry a molecule from the earliest stages all the way to the clinic.